登记号 Registration number	CTR20222569	试验状态 Trial status	进行中 Ongoing
申请人联系人 Applicant Contact	夏言言 Xia Yanyan	首次公示信息日期 The date on which the information was first published	2022-10-12
申请人名称 Name of applicant	不适用/ 默克雪兰诺（北京）医药研发有限公司  N/A / Merck Seronno (Beijing) Pharmaceutical R&D Co., Ltd

登记号 Registration number	CTR20222569
相关登记号 Relevant registration number
药物名称 The name of the drug	Xevinapant口服溶液   曾用名:Debio 1143 Xevinapant Oral Solution formerly known as Debio 1143
药物类型 Type of medication	化学药物  Chemical drugs
临床申请受理号  Clinical application acceptance number	企业选择不公示  The company chooses not to make it public
适应症 Indications	Xevinapant联合放疗（RT）适用于具有高复发风险且不适宜含顺铂化疗的已手术切除的局部晚期SCCHN的患者 Xevinapant plus radiotherapy (RT) is indicated for patients with surgically resected locally advanced SCCHN who are at high risk of recurrence and who are not candidates for cisplatin-based chemotherapy
试验专业题目 Experimental professional topics	一项在具有高复发风险且不适宜高剂量顺铂的已手术切除的头颈部鳞状细胞癌受试者中评估xevinapant和放疗与安慰剂和放疗相比的有效性和安全性并证明无病生存期改善的随机、双盲、安慰剂对照、双臂III期研究 A randomized, double-blind, placebo-controlled, two-arm phase III study to evaluate the efficacy and safety of xevinapant and radiotherapy compared with placebo and radiotherapy and demonstrate improved disease-free survival in subjects with surgically resected head and neck squamous cell carcinoma at high risk of recurrence who are not candidates for high-dose cisplatin
试验通俗题目 Experiment with popular topics	一项xevinapant和放疗联合治疗具有高风险且不适宜顺铂的已手术切除的LA SCCHN受试者的III期研究 A Phase III study of xevinapant in combination with radiotherapy in subjects with surgically resected LA SCCHN who are at high risk and not candidates for cisplatin
试验方案编号 Protocol number	MS202359_0002	方案最新版本号  The latest version of the solution	第5.0版  Version 5.0
版本日期: Version Date:	2023-07-25	方案是否为联合用药 Whether the regimen is a combination of drugs	否

申请人名称 Name of applicant	1 2
联系人姓名 Contact name	夏言言 Xia Yanyan	联系人座机 Contact desk phone	021-22265500	联系人手机号 The contact's mobile phone number	18758189762
联系人Email Contact Email	ellie.xia@external.merckgroup.com	联系人邮政地址 Contact person postal address	上海市-上海市-浦东新区东育路227弄3号前滩世贸中心（二期）C栋15层 15th Floor, Building C, Qiantan World Trade Center (Phase II), No. 3, Lane 227, Dongyu Road, Shanghai - Pudong New Area	联系人邮编 Contact zip code	200126

本研究的目的是，证明xevinapant当添加到放疗方案时在不适宜接受以顺铂为基础的放化疗同步治疗的患有已手术切除的LA SCCHN的高风险受试者中的有效性优于安慰剂。
The purpose of this study is to demonstrate that xevinapant, when added to a radiotherapy regimen, is superior to placebo in high-risk subjects with surgically resected LA SCCHN who are not candidates for concomitant cisplatin-based chemoradiotherapy.

试验分类 Classification of trials	安全性和有效性  Safety and efficacy	试验分期 Staging of the trial	III期  Stage III	设计类型 Type of design	平行分组  Parallel grouping
随机化 randomization	随机化  randomization	盲法 Blinding	双盲  Double-blind	试验范围 Scope of the test	国际多中心试验  International multicenter trial

年龄 age	18岁(最小年龄)至 无上限 (最大年龄)  18 years old (minimum age) to no upper limit (maximum age)
性别 gender	男+女  Male + Female
健康受试者 Healthy subjects	无
入选标准 Inclusion Criteria	1 签署知情同意书时年满18岁（或者根据国家法定成人年龄限制[如果>18岁的话]）。 Be at least 18 years of age at the time of signing the informed consent form (or according to the national legal age limit for the adult [if > 18 years old]). 2 ECOG PS为0-2分，并且根据研究者的评估，能够耐受IMRT标准治疗。 ECOG PS score of 0-2 and, as assessed by the investigator, able to tolerate standard treatment with IMRT. 3 以下原发部位之一患有组织学确诊的鳞状细胞癌：口腔、口咽、下咽或喉。受试者在开始治疗（C1D1）前的过去4至8周内在这些部位接受了根治性手术（注：患有2种或2种以上原发性SCCHN肿瘤的受试者不适合参与本研究）。 Histologically confirmed squamous cell carcinoma at one of the following primary sites: oral cavity, oropharynx, hypopharynx, or larynx. Subjects have undergone radical surgery at these sites within the past 4 to 8 weeks prior to initiation of treatment (C1D1) (Note: subjects with 2 or more primary SCCHN tumors are not suitable for participation in this study). 4 通过使用免疫组织化学（IHC）检测p16表达确定患有HPV阴性口咽癌的受试者，患有以下病理分期（根据美国癌症联合委员会AJCC/TNM分期系统第8版的pTNM分期）的口腔癌、下咽癌或喉癌的受试者： pIII或 pIVA或pIVB 或 通过使用IHC检测p16表达确定患有HPV阳性口咽癌的受试者，他们必须为25包-年的吸烟者，且必须具有以下pTNM分期（根据AJCC/TNM分期系统第8版）： pT3和pN2或 pT4和pN2 OPC受试者必须有已知的HPV状态，通过使用IHC检测p16表达确定（应提供病理报告）。 Subjects with HPV-negative oropharyngeal carcinoma as determined by immunohistochemistry (IHC) detection of p16 expression, subjects with the following pathologic stages (pTNM staging according to the American Joint Committee on Cancer AJCC/TNM Staging System, 8th Edition): pIII or pIVA or pIVB or Subjects with HPV-positive oropharyngeal carcinoma identified by IHC detection of p16 expression, they must be smokers of 25 pack-years, and must have the following pTNM staging (according to AJCC/TNM staging system version 8): pT3 and pN2 or pT4 and pN2 OPC subjects must have known HPV status, as determined by testing for p16 expression using IHC (pathology report should be provided). 5 如果当地法规允许，必须提供受试者的存档/放疗前FFPE肿瘤组织样本。 If local regulations allow, an archived/pre-radiotherapy FFPE tumor tissue sample from the subject must be provided. 6 通过CT和18F-FDG-PET检测无残留病灶，并具有符合1项或2项以下标准的高复发风险，并经当地组织病理学检查确认： 结节包膜外侵犯（ECE） 阳性切缘（R1或密切切缘≤1 mm）。 No residual disease detected by CT and 18F-FDG-PET with a high risk of recurrence that meets 1 or 2 of the following criteria, and confirmed by local histopathological examination: Nodular extracapsular invasion (ECE) Positive margins (R1 or close margins≤ 1 mm). 7 具有允许进行术后放疗的术后一般条件。  Has a postoperative general condition that allows for postoperative radiotherapy. 8 能够吞咽液体或放置足够功能的喂饲管、行胃造瘘术或空肠造口术。 Able to swallow liquids or place an adequately functional feeding tube, and have a gastrostomy or jejunostomy. 9 符合以下一项或多项标准不适宜接受高剂量顺铂：30 mL/min/1.73m的平方 High doses of cisplatin are not suitable if one or more of the following criteria are met: 30 mL/min/1.73 m squared 10 有足够的血液学和肝功能  Adequate hematologic and hepatic function 11 允许所有性别的受试者 避孕药的使用应符合当地对参与临床研究人员避孕方法的规定。 Subjects of all genders are allowed to use contraceptives in accordance with local regulations for contraceptive methods in participating clinical investigators. 12 能够提供签名的知情同意书，其中包括符合ICF和本方案中所列的要求和限制。 Able to provide signed informed consent that includes compliance with the requirements and restrictions listed in the ICF and this protocol.
排除标准 Exclusion Criteria:	1 研究者认为对参与研究构成不适当风险或禁忌症或可能干扰研究目的、进行或评价的任何疾病，包括除SCCHN以外的任何未控制的疾病状态。 Any disease that, in the opinion of the investigator, poses an undue risk or contraindication to participation in the study or may interfere with the purpose, conduct, or evaluation of the study, including any uncontrolled disease state other than SCCHN. 2 鼻咽、副鼻窦、鼻腔、唾液腺、甲状腺或甲状旁腺、皮肤或未知原发部位的原发性肿瘤。 Primary tumors of the nasopharynx, paranasal sinuses, nasal cavity, salivary glands, thyroid or parathyroid glands, skin, or unknown primary site. 3 未完全切除手术（即R2切除）的受试者（AJCC/TNM，第8版）。 Subjects with incomplete resection surgery (i.e., R2 resection) (AJCC/TNM, 8th edition). 4 复发或转移性疾病（IVC期，根据AJCC/TNM，第8版）。 Recurrent or metastatic disease (stage IVC, according to AJCC/TNM, 8th edition). 5 已知的HIV感染史。  Known history of HIV infection. 6 慢性活动性HBV或HCV感染。  Chronic active HBV or HCV infection. 7 需要全身治疗的其他感染（病毒性[包括COVID-19]和/或细菌性和/或真菌性） Other infections requiring systemic treatment (viral [including COVID-19] and/or bacterial and/or fungal) 8 已知的胃肠疾病，具有临床确定的吸收不良综合征，并且在过去12个月内进行了可能限制口服吸收的重大胃肠外科手术。 Known gastrointestinal disease with clinically determined malabsorption syndrome and major gastrointestinal surgery within the past 12 months that may limit oral absorption. 9 在术前最近4周内记录的体重下降>10%（除非采取了足够的营养支持措施），或血浆白蛋白<3.0 g/dL。随机化前2周内不允许输注白蛋白。 Weight loss of >10% (unless adequate nutritional support measures) or plasma albumin < 3.0 g/dL recorded in the last 4 weeks prior to surgery. Albumin infusion is not allowed for 2 weeks prior to randomization. 10 活动性胃肠出血，或任何其他需要2次以上红细胞输注的控制不佳的出血，或在随机化前4周内输注过4个单位及以上的浓缩红细胞。 Active gastrointestinal bleeding, or any other poorly controlled bleeding requiring more than 2 red blood cell transfusions, or transfusion of 4 or more units of packed red blood cells within 4 weeks prior to randomization. 11 需要持续接受抗TNF药物治疗的活动性炎症性疾病。 Active inflammatory disease requiring ongoing anti-TNF drug therapy. 12 心血管功能受损、有临床意义的心血管疾病或有临床意义的肺部疾病 Impaired cardiovascular function, clinically significant cardiovascular disease, or clinically significant pulmonary disease 13 随机化之前有其他恶性肿瘤病史，但以下除外：完全切除的头颈部以外的非黑色素瘤细胞皮肤癌或完全切除的I期乳腺癌或完全切除的原位非肌肉浸润性膀胱癌、宫颈癌和/或子宫癌或T1a食管鳞癌除外。 既往患有恶性肿瘤，接受过根治性治疗，在过去3年内没有复发，也没有抗癌治疗，并且不会干扰研究的安全性或有效性评估。 History of other malignancies prior to randomization, with the exception of the following: completely resected non-melanoma cell skin cancer other than the head and neck or completely resected stage I breast cancer or completely resected orthotopic non-muscle-invasive bladder cancer, cervical cancer, and/or uterine cancer or T1a esophageal squamous cell carcinoma. Prior malignancy, curative therapy, no recurrence within the past 3 years, and no anti-cancer therapy, and that would not interfere with the safety or efficacy assessment of the study. 14 非代偿性或症状性肝硬化（Child-Pugh评分：B或C）。 Uncompensated or symptomatic cirrhosis (Child-Pugh score: B or C). 15 先前对头颈部区域进行的可能影响原发肿瘤放疗计划的根治性、新辅助、同步或辅助（化）放疗，或任何其他既往SCCHN全身性治疗，包括试验性药物。 Prior curative, neoadjuvant, concurrent or adjuvant (chemical) radiotherapy to the head and neck region that may affect the radiotherapy plan for the primary tumor, or any other prior systemic therapy for SCCHN, including investigational agents. 16 使用以下治疗： 禁用药物。第6.8.3节进一步规定了这些药物和随机化前停用这些药物的时间窗。 在第一次研究治疗前4周内或在研究治疗期间，使用试验性药物或使用试验性器械治疗。 第一次研究治疗前28天内接种减毒活疫苗。 合并使用抗癌治疗。 The following treatments are used: Drugs are contraindicated. Section 6.8.3 further sets out the time window for these drugs and to discontinue them prior to randomization. Use of an investigational drug or treatment with an investigational device within 4 weeks prior to the first dose of study treatment or during study treatment. Administration of live attenuated vaccine within 28 days prior to the first dose of study treatment. Concomitant use of anticancer therapy. 17 活动性免疫缺陷患者或正在接受免疫抑制治疗的患者。 Patients with active immunodeficiency or those receiving immunosuppressive therapy. 18 在开始治疗前7天内，任何已知会延长QT间期且不能停药或通过安全替代药物替代的合并用药。 Any concomitant medication known to prolong the QT interval within 7 days prior to initiation of treatment and cannot be discontinued or replaced by a safe alternative medication. 19 在接受第一剂研究治疗前4周内接受过头颈部区域以外的重大外科干预治疗。允许进行活检以确定对SCCHN的诊断。 Significant surgical intervention outside the head and neck region within 4 weeks prior to receiving the first dose of study treatment. Biopsy is allowed to confirm the diagnosis of SCCHN. 20 既往器官移植，包括同种异体干细胞移植。  Prior organ transplantation, including allogeneic stem cell transplantation. 21 筛选前28天内或参与本研究期间参与任何其他临床研究。 Participation in any other clinical study within 28 days prior to screening or during participation in this study. 22 已知禁忌接受正电子发射断层扫描及18F-FDG-PET-CT扫描或对比剂增强的MRI和对比剂增强的CT扫描。 Positron emission tomography with 18F-FDG-PET-CT scan or contrast-enhanced MRI and contrast-enhanced CT scans are known to contraindicate undergoing positron emission tomography. 23 已知对xevinapant或xevinapant或安慰剂制剂中已知存在的任何辅料过敏。 Known hypersensitivity to xevinapant or any excipient known to be present in xevinapant or placebo formulations. 24 妊娠或授乳（哺乳）期女性。  Pregnant or lactating (lactating) females. 25 任何社会、个人、医疗和/或心理因素，包括目前的酒精和/或药物滥用，可能会影响研究者对受试者遵守方案和/或随访和/或知情同意书签署情况的判断。 Any social, personal, medical, and/or psychological factors, including current alcohol and/or drug abuse, that may affect the investigator's judgment regarding the subject's compliance with the protocol and/or follow-up and/or the signing of the informed consent form.

试验药 Investigational drug

序号 serial number 名称 name 用法 usage 1 中文通用名:Xevinapant口服溶液  Chinese generic name: Xevinapant oral solution 英文通用名:Xevinapant Oral Solution 商品名称:NA   Product name: NA 剂型:口服溶液剂  Dosage form: oral solution 规格:200mg(20mg/ml)  Specification: 200mg(20mg/ml) 用法用量:200 mg/ 天  Dosage: 200 mg/day 用药时程:3个周期的xevinapant（口服溶液200 mg/天，第1天-第14天，每3周一个周期）＋IMRT（66 Gy/33次分割，2 Gy/分割，5天/周），随后为3个周期的xevinapant单药治疗（口服溶液200 mg/天，第1天-第14天，每3周一个周期） Duration of administration: 3 cycles of xevinapant (200 mg/day orally, day 1-14, every 3 weeks) + IMRT (66 Gy/33 fractions, 2 Gy/fraction, 5 days/week), followed by 3 cycles of xevinapant monotherapy (200 mg/day orally, days 1-14, every 3-week cycle) 2 中文通用名:Xevinapant口服溶液  Chinese generic name: Xevinapant oral solution 英文通用名:Xevinapant Oral Solution 商品名称:NA   Product name: NA 剂型:口服溶液剂  Dosage form: oral solution 规格:200mg(20mg/ml)  Specification: 200mg(20mg/ml) 用法用量:200 mg/ 天  Dosage: 200 mg/day 用药时程:3个周期的xevinapant（口服溶液200 mg/天，第1天-第14天，每3周一个周期）＋IMRT（66 Gy/33次分割，2 Gy/分割，5天/周），随后为3个周期的xevinapant单药治疗（口服溶液200 mg/天，第1天-第14天，每3周一个周期） Duration of administration: 3 cycles of xevinapant (200 mg/day orally, day 1-14, every 3 weeks) + IMRT (66 Gy/33 fractions, 2 Gy/fraction, 5 days/week), followed by 3 cycles of xevinapant monotherapy (200 mg/day orally, days 1-14, every 3-week cycle)

对照药 Comparator

序号 serial number 名称 name 用法 usage 1 中文通用名:安慰剂  Chinese generic name: placebo 英文通用名:Placebo  Common name in English: Placebo 商品名称:NA   Product name: NA 剂型:口服溶液剂  Dosage form: oral solution 规格:200mg(20mg/ml)  Specification: 200mg(20mg/ml) 用法用量:200 mg/天  Dosage: 200 mg/day 用药时程:3个周期的安慰剂（相匹配口服溶液，第1天-第14天，每3周一个周期）＋IMRT（66 Gy/33次分割，2 Gy/分割，5天/周），随后为3个周期的安慰剂单药治疗（相匹配口服溶液，第1天-第14天，每3周一个周期） Duration of administration: 3 cycles of placebo (matching oral solution, day 1-14, every 3 weeks cycle) + IMRT (66 Gy/33 fractions, 2 Gy/fraction, 5 days/week), followed by 3 cycles of placebo monotherapy (matching oral solution, day 1-14, every 3 weeks cycle) 2 中文通用名:安慰剂  Chinese generic name: placebo 英文通用名:Placebo  Common name in English: Placebo 商品名称:NA   Product name: NA 剂型:口服溶液剂  Dosage form: oral solution 规格:200mg(20mg/ml)  Specification: 200mg(20mg/ml) 用法用量:200 mg/天  Dosage: 200 mg/day 用药时程:3个周期的安慰剂（相匹配口服溶液，第1天-第14天，每3周一个周期）＋IMRT（66 Gy/33次分割，2 Gy/分割，5天/周），随后为3个周期的安慰剂单药治疗（相匹配口服溶液，第1天-第14天，每3周一个周期） Duration of administration: 3 cycles of placebo (matching oral solution, day 1-14, every 3 weeks cycle) + IMRT (66 Gy/33 fractions, 2 Gy/fraction, 5 days/week), followed by 3 cycles of placebo monotherapy (matching oral solution, day 1-14, every 3 weeks cycle) 3 中文通用名:安慰剂  Chinese generic name: placebo 英文通用名:Placebo  Common name in English: Placebo 商品名称:NA   Product name: NA 剂型:口服溶液剂  Dosage form: oral solution 规格:200mg(20mg/ml)  Specification: 200mg(20mg/ml) 用法用量:200 mg/天  Dosage: 200 mg/day 用药时程:3个周期的安慰剂（相匹配口服溶液，第1天-第14天，每3周一个周期）＋IMRT（66 Gy/33次分割，2 Gy/分割，5天/周），随后为3个周期的安慰剂单药治疗（相匹配口服溶液，第1天-第14天，每3周一个周期） Duration of administration: 3 cycles of placebo (matching oral solution, day 1-14, every 3 weeks cycle) + IMRT (66 Gy/33 fractions, 2 Gy/fraction, 5 days/week), followed by 3 cycles of placebo monotherapy (matching oral solution, day 1-14, every 3 weeks cycle)

主要终点指标及评价时间 The main endpoint indicators and evaluation time

序号 serial number 指标 index 评价时间 Evaluation time 终点指标选择 Endpoint metric selection 1 从随机化到以下任何事件首次发生的时间（在末次可评价评估或随机化后的2次计划DFS评估内发生）： 因任何原因死亡 客观疾病复发 Time from randomization to the first occurrence of any of the following events (occurring within the last evaluable assessment or 2 planned DFS assessments after randomization): Death due to any cause Objective disease recurrence 直至20周 Up to 20 weeks 有效性指标  Effectiveness metrics

次要终点指标及评价时间 Secondary endpoint measures and evaluation time

序号 serial number 指标 index 评价时间 Evaluation time 终点指标选择 Endpoint metric selection 1 从随机化日期到死亡日期的时间。 Time from the date of randomization to the date of death. 直至20周 Up to 20 weeks 有效性指标  Effectiveness metrics 2 至后续癌症治疗的时间，从随机化到开始第一次后续癌症治疗的时间 Time to follow-up cancer treatment, from randomization to initiation of first follow-up cancer treatment 直至20周 Up to 20 weeks 有效性指标  Effectiveness metrics 3 发生AE和治疗相关AE Occurrence of AEs and treatment-related AEs 直至20周 Up to 20 weeks 安全性指标  Safety metrics 4 EORTC QLQ-HN35子量表评分（头颈部疼痛、吞咽困难和讲话困难）相对于基线的变化 Change from baseline in EORTC QLQ-HN35 subscale score (head and neck pain, dysphagia, and difficulty speaking). 直至20周 Up to 20 weeks 有效性指标+安全性指标  Effectiveness index + safety index 5 EORTC QLQ-C30子量表评分（疲乏、身体功能和总体健康状况）相对于基线的变化 Change from baseline in EORTC QLQ-C30 subscale score (fatigue, physical function, and general health status). 直至20周 Up to 20 weeks 有效性指标+安全性指标  Effectiveness index + safety index 6 EQ-5D-5L VAS相对于基线的变化 Change from baseline in EQ-5D-5L VAS 直至20周 Up to 20 weeks 有效性指标+安全性指标  Effectiveness index + safety index

有 有

1	姓名 name	杨坤禹 Yang Kunyu	学位 degree	医学博士 MD	职称 job title	正高级 It is advanced
	电话 Phone	13995595360	Email	yangky71@aliyun.com	邮政地址 Postal address	湖北省-武汉市-江汉路解放大道1277号 Hubei Province - Wuhan City - Jianghan Road Jiefang Avenue No. 1277
	邮编 Zip	430022	单位名称 The name of the organization	华中科技大学同济医学院附属协和医院 Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology

序号 serial number	机构名称 Name of the institution	主要研究者 Principal Investigator	国家或地区 Country	省（州） Province (State)	城市 city
1	华中科技大学同济医学院附属协和医院 Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology	杨坤禹 Yang Kunyu	中国 China	湖北省 Hubei Province	武汉市 Wuhan
2	湖南省肿瘤医院 Hunan Provincial Cancer Hospital	韩亚骞 Han Yaqian	中国 China	湖南省 Hunan Province	长沙市 Changsha city
3	福建省肿瘤医院 Fujian Provincial Cancer Hospital	林少俊 Lin Shaojun	中国 China	福建省 Fujian Province	福州市 Fuzhou City
4	浙江大学医学院附属邵逸夫医院 Sir Run Run Shaw Hospital, Zhejiang University School of Medicine	孙晓南 Sun Xiaonan	中国 China	浙江省 Zhejiang Province	杭州市 Hangzhou City
5	浙江省肿瘤医院 Zhejiang Provincial Cancer Hospital	陈晓钟 Chen Xiaozhong	中国 China	浙江省 Zhejiang Province	杭州市 Hangzhou City
6	苏北人民医院 Subei People's Hospital	汪步海 Wang Buhai	中国 China	江苏省 Jiangsu Province	扬州市 Yangzhou City
7	四川大学华西医院 West China Hospital, Sichuan University	刘磊 Liu Lei	中国 China	四川省 Sichuan Province	成都市 Chengdu City
8	山东省肿瘤医院 Shandong Provincial Cancer Hospital	胡漫 Hu Man	中国 China	山东省 Shandong Province	济南市 Jinan city
9	重庆大学附属肿瘤医院 Affiliated Cancer Hospital of Chongqing University	谢悦 Xie Yue	中国 China	重庆市 Chongqing Municipality	重庆市 Chongqing Municipality
10	江西省肿瘤医院 Jiangxi Provincial Cancer Hospital	李金高 Li Jingao	中国 China	江西省 Jiangxi Province	南昌市 Nanchang city
11	四川省肿瘤医院 Sichuan Provincial Cancer Hospital	冯梅 Feng Mei	中国 China	四川省 Sichuan Province	成都市 Chengdu City
12	吉林大学第一医院 The First Hospital of Jilin University	姜新 Jiang Xin	中国 China	吉林省 Jilin Province	长春市 Changchun city
13	广西壮族自治区肿瘤医院 (广西医科大学附属肿瘤医院) Guangxi Zhuang Autonomous Region Cancer Hospital (Affiliated Cancer Hospital of Guangxi Medical University)	曲颂 Song Song	中国 China	广西壮族自治区 Guangxi Zhuang Autonomous Region	南宁市 Nanning
14	天津市肿瘤医院 Tianjin Cancer Hospital	王佩国 Wang Peiguo	中国 China	天津市 Tianjin City	天津市 Tianjin City
15	复旦大学附属肿瘤医院 Fudan University Cancer Hospital	胡超苏 Hu Chaosu	中国 China	上海市 Shanghai	上海市 Shanghai
16	Instituto de Oncologia Angel Roffo	Giglio, Raul Eduardo	Argentina	Ciudad Autonoma Buenos Aires	Ciudad Autonoma Buenos Aires
17	Centro Oncologico Riojano Integral (CORI)	Kaen, Diego Lucas	Argentina	La Rioja	La Rioja
18	Clinica Viedma S.A.	Kowalyszyn, Ruben	Argentina	Rio Negro	Viedma
19	CEMAIC - Centro Medico Privado	Salinas, Jorge Emilio	Argentina	Cordoba	Cordoba
20	Fundacion Scherbovsky	Sola, Alejandro	Argentina	Mendoza	Mendoza
21	Krankenhaus der barmherzigen Schwestern Linz	Burian, Martin	Austria	NA	Linz
22	LKH - Universitatsklinikum der PMU Salzburg	Greil, Richard	Austria	NA	Salzburg
23	LKH - Universitatsklinikum Graz	Thurnher, Dietmar	Austria	NA	Graz
24	Cliniques Universitaires Saint-Luc	Machiels, Jean-Pascal	Belgium	NA	Bruxelles
25	UZA	Rasschaert, Marika	Belgium	NA	Namur
26	Oncosite - Centro de Pesquisa Clinica e Oncologia	Andre Franke, Fabio	Brazil	Rio Grande do Sul	Ijui
27	Irmandade da Santa Casa de Misericordia de Porto Alegre	Arima Tiscoski, Katsuki	Brazil	Rio Grande do Sul	Porto Alegre
28	HGB - Hospital Giovanni Battista - Mae de Deus Center HGB - Hospital Giovanni Battista - Mother of God Center	Arrieira Azambuja, Alan	Brazil	Rio Grande do Sul	Porto Alegre
29	Hospital de Cancer de Barretos - Fundacao Pio XII Barretos Cancer Hospital - Pius XII Foundation	Baston Silva, Carlos	Brazil	Sao Paulo	Barretos
30	INCA - Instituto Nacional de Cancer	Dutra, Jamille	Brazil	Rio do Janeiro	Rio do Janeiro
31	Hospital de Clínicas de Porto Alegre	Jobim de Azevedo, Sergio	Brazil	Rio Grande do Sul	Porto Alegre
32	Instituto de Cancer de Londrina	Menacho de Oliveira, Rivadavio Antunes	Brazil	Parana	Londrina
33	Hospital Erasto Gaertner - Liga Paranaense de Combate ao Cancer Erasto Gaertner Hospital - Paranaense League for the Fight against Cancer	Martinelli de Oliveira, Fabrício Augusto	Brazil	Martinelli de Oliveira, Fabrício Augusto	Curitiba
34	Grupo Oncoclínicas	Martins De Marchi, Pedro Rafael	Brazil	Rio do Janeiro	Rio do Janeiro
35	ICESP - Instituto do Cancer do Estado de S？o Paulo Octavio Frias de Oliveira ICESP - Cancer Institute of the State of São Paulo Octavio Frias de Oliveira	Perez Mak, Milena	Brazil	Sao Paulo	Sao Paulo
36	CRIO - Centro Regional Integrado de Oncologia	Pinto Figueiredo Lima, Iane	Brazil	Ceará	Fortaleza
37	CEPON - Centro de Pesquisas Oncológicas de Santa Catarina	Pontes Grando, Fabricio	Brazil	Santa Catarina	Florianópolis
38	Liga Norte-Rio-Grandense Contra o Cancer	Sales, Silvio	Brazil	Rio Grande do Norte	Natal
39	CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia CEPHO - Center for Studies and Research in Hematology and Oncology	Vaz de Melo Sette, Claudia	Brazil	Sao Paulo	Santo Andre
40	Hospital Beneficencia Portuguesa de Sao Paulo	Vieira dos Santos, Lucas	Brazil	Vieira dos Santos, Lucas	Sao Paulo
41	Fakultni nemocnice Bulovka	Holeckova, Petra	Czech Republic	NA	Praha
42	Fakultni nemocnice Olomouc	Melichar, Bohuslav	Czech Republic	NA	Olomouc
43	Hopital Prive Drome Ardeche	Bosset, Matthieu	France	Ardeche	Guilherand Granges
44	CHU Tours - Hopital Bretonneau	Chapet, Sophie	France	Indre et Loire	Tours cedex
45	CHU Bordeaux	Daste, Amaury	France	Gironde	Bordeaux cedex
46	Hopital Tenon	Huguet, Florence	France	Paris	Paris
47	Centre Azureen Cancerologie	Lenglet, Alexis	France	Alpes Maritimes	Mougins
48	Centre Oscar Lambret	Liem, Xavier	France	Nord	Lille cedex
49	ICO - Site René Gauducheau	Rolland, Frederic	France	Loire Atlantique	Saint Herblain
50	Hopital de la Timone	Salas, Sebastien	France	Bouches-du-Rh？ne Bouches-du-Rh？ ne	Marseille Cedex 5
51	CHU Brest - Hopital Morvan	Schick, Ulrike	France	Finistere	Brest Cedex
52	Institut Gustave Roussy	Tao, Yungan	France	Val de Marne	Villejuif cedex
53	CHI Toulon La Seyne - Hopital Sainte Musse	Tchiknavorian, Xavier	France	Var	Toulon cedex
54	Centre Henri Becquerel	Thureau, Sebastien	France	Seine Maritime	Rouen
55	Centre Georges Francois Leclerc	Vulquin, Noemie	France	Cote-d'Or	Dijon Cedex
56	Universitaetsklinikum Schleswig-Holstein - Campus Kiel University Medical Center Schleswig-Holstein - Campus Kiel	Domschikowski, Justus	Germany	Schleswig Holstein	Kiel
57	Universitaetsklinikum Jena	Guntinas-Lichius, Orlando	Germany	Thueringen	Jena
58	Universitaetsmedizin Rostock	Hildebrandt, Guido	Germany	Mecklenburg Vorpommern	Rostock
59	Universitaetsklinikum Leipzig	Kuhnt, Thomas	Germany	Bayern	Regensburg
60	Universitaetsklinikum Giessen und Marburg GmbH	Langer, Christine	Germany	Hessen	Marburg
61	Vivantes Klinikum Neukoelln	de Wit, Maike	Germany	Berlin	Berlin
62	Caritasklinik St. Theresia	Topaly, Julian	Germany	Saarland	Saarbruecken
63	Tata Medical Centre	Chatterjee, Sanjoy	India	West Bengal	Kolkata
64	Regional Cancer Centre	Kumar, Rejnish	India	Kerala	Thiruvananthapuram
65	National Cancer Institute Nagpur	Pathak, Anand	India	Maharashtra	Nagpur
66	Chaim Sheba Medical Center	Gluck, Iris	Israel	NA	Ramat Gan
67	Soroka University Medical Center	Meirovitz, Amichay	Israel	NA	Beer sheva
68	Hadassah University Hospital - Ein Kerem	Popovtzer, Aron	Israel	NA	Yerushalayim
69	Rambam Health Care Center	Salman, Saeed	Israel	NA	Haifa
70	University of Pittsburgh Medical Center Health System	Ferris, Robert	United States	Pennsylvania	Pittsburgh
71	Montefiore Medical Center Radiology	Kabarriti, Rafi	United States	New York	Bronx
72	Greenville Hospital System University Medical Center (ITOR)	O'Neal, Richard	United States	South Carolina	Greenville
73	Barbara Ann Karmanos Cancer Institute	Sukari, Ammar	United States	Michigan	Detroit
74	University of Cincinnati Cancer Institute	Medek, Sara	United States	Ohio	Cincinnati
75	Dana-Farber Cancer Institute	Haddad, Robert	United States	Massachusetts	Boston
76	University of Alabama at Birmingham	Bonner, James	United States	Alabama	Birmingham
77	Perlmutter Cancer Center at NYU Langone Hospital ae Long Island	Li, Zujun	United States	New York	New York
78	CHUM Centre de Recherche	Soulieres, Denis	Canada	Quebec	Montreal
79	Centro de Atencion e Investigacion Clinica en Oncologia	Molina Alavez, Alejandro	Mexico	Yucatan	Merida
80	Antiguo Hospital Civil de Guadalajara Fray Antonio Alcalde	Ramirez Godinez, Francisco Javier	Mexico	Jalisco	Guadalajara
81	Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez Universidad Autónoma de Nuevo León, Hospital Universitario Dr. José Eleuterio González	Oyervides Juarez, Victor Manuel	Mexico	Nuevo Leon	Monterrey
82	Hospital Santa Izabel - Santa Casa de Misericordia da Bahia	Brito, Daniel	Brazil	Bahia	Salvador
83	Yokohama City University Hospital	Oridate, Nobuhiko	Japan	Kanagawa-Ken	Yokohama-shi
84	NHO Hokkaido Cancer Center	Ueda, Michihiro	Japan	Hokkaido	Sapporo-shi
85	Osaka International Cancer Institute	Fujii, Takashi	Japan	Osaka-Fu	Osaka-shi
86	Cancer Institute Hospital of JFCR	Tomomatsu, Junichi	Japan	Tokyo-To	Koto-ku
87	Aichi Cancer Center Hospital	Hanai, Nobuhiro	Japan	Aichi-Ken	Nagoya-shi
88	Kindai University Hospital	Tanaka, Kaoru	Japan	Osaka-Fu	Osakasayama-shi
89	Hiroshima University Hospital	Ueda, Tsutomu	Japan	Hiroshima-Ken	Hiroshima-shi
90	National Cancer Center Hospital	Murakami, Naoya	Japan	Tokyo-To	Chuo-ku
91	Okayama University Hospital	Ando, Mizuo	Japan	Okayama-Ken	Okayama-shi
92	National Cancer Center Hospital East	Tahara, Makoto	Japan	Chiba-Ken	Kashiwa-shi
93	Nagoya University Hospital	Nishio, Naoki	Japan	Aichi-Ken	Nagoya-shi
94	Kobe University Hospital	Kiyota, Naomi	Japan	Hyogo-Ken	Kobe-shi
95	Tohoku University Hospital	Katori, Yukio	Japan	Miyagi-Ken	Sendai-shi
96	Saitama Cancer Center	Shirakura, Satoshi	Japan	Saitama-Ken	Kitaadachi-gun
97	Kagawa University Hospital	Okita, Yoshihiro	Japan	Kagawa-Ken	Kita-gun
98	Pusan National University Yangsan Hospital	Oh, So Yeon	Korea, Republic of	Gyeongsangnam-do	Yangsan-si
99	Seoul National University Bundang Hospital	Kim, Ji-Won	Korea, Republic of	Gyeonggi-do	Seongnam
100	Severance Hospital, Yonsei University Health System	Kim, Hye Ryun	Korea, Republic of	NA	Seoul
101	Chonnam National University Hwasun Hospital	Shim, Hyun Jeong	Korea, Republic of	Jeollanam-do	Hwasun-gun
102	Seoul National University Hospital	Keam, Bhumsuk	Korea, Republic of	NA	Seoul
103	Konkuk University Medical Center	Park, Ji-Hyun	Korea, Republic of	NA	Seoul
104	The Catholic University of Korea, St. Vincent's Hospital	An, Ho Jung	Korea, Republic of	Gyeonggi-do	Suwon-si
105	Korea University Anam Hospital	Shin, Sang-Won	Korea, Republic of	NA	Seoul
106	Kaohsiung Medical University Chung-Ho Memorial Hospital	Wang, Hui-Ching	中国台湾 Taiwan, China	NA	Kaohsiung
107	National Taiwan University Hospital	Lou, Pei-Jen	中国台湾 Taiwan, China	NA	Taipei
108	National Cheng Kung University Hospital	Wu, Shang-Yin	中国台湾 Taiwan, China	NA	Tainan
109	Kaohsiung Chang Gung Memorial Hospital	Chiu, Tai-Jan	中国台湾 Taiwan, China	NA	Kaohsiung
110	Chi Mei Hospital, Liouying	Lin, Chien-Liang	中国台湾 Taiwan, China	NA	Tainan
111	Chang Gung Memorial Hospital,Linkou	Chang, Tung-Chieh	中国台湾 Taiwan, China	NA	Taoyuan County
112	Taipei Veterans General Hospital	Yang, Muh-Hwa	中国台湾 Taiwan, China	NA	Taipei City
113	China Medical University Hospital	Lien, Ming-Yu	中国台湾 Taiwan, China	NA	Taichung
114	Changhua Christian Medical Foundation Changhua Christian Hospital	Lin, Jin-Ching	中国台湾 Taiwan, China	NA	Changhua
115	Tata Memorial Hospital	Noronha, Vanita	India	Maharashtra	Mumbai
116	All India Institute of Medical Sciences	Sharma, Atul	India	Delhi	New Delhi
117	KABEG-Klinikum Klagenfurt	Eckel, Hans Edmund	Austria	NA	Klagenfurt am Worthersee
118	Vitaz	Lybaert, Willem	Belgium	NA	Sint Niklaas
119	Fakultni nemocnice Kralovske Vinohrady	Lickova, Katerina	Czech Republic	NA	Praha 10
120	Clinique Victor Hugo - Centre Jean Bernard	Pointreau, Yoann	France	Sarthe	Le Mans Cedex 02
121	Centre Hospitalier Prive Saint-Gregoire (Rennes)	Riet, Francois Georges	France	Ille et Vilaine	Saint Gregoire
122	Institut Regional du Cancer de Montpellier	Boisselier, Pierre	France	Herault	Montpellier
123	ICO - Site Paul Papin	Goineau, Aurore	France	Maine et Loire	Angers Cedex 2
124	Centre Hospitalier de la Croix Rousse	Lapierre, Ariane	France	Rhone	Criox-Rousse
125	Centre Antoine Lacassagne	Saada-Bouzid, Esma	France	Alpes Maritimes	Nice
126	CHU Poitiers - Hopital la Miletrie	Evrard, Camille	France	Vienne	Poitiers
127	Institut Claudius Regaud	Modesto, Anouchka	France	Haute Garonne	Toulouse cedex 09
128	Institut de Cancerologie de Strasbourg Europe - ICANS	Borel, Christian	France	Bas Rhin	Strasbourg
129	Centre Hospitalier de Bretagne Sud	Sire, Christian	France	Morbihan	Lorient cedex
130	High Technology Medical Center, University Clinic	Gogishvili, Miranda	Georgia	NA	Tbilisi
131	New Hospitals	Giorgadze, Davit	Georgia	NA	Tbilisi
132	Interbalkan Hospital of Thessaloniki	Baka, Sofia	Greece	NA	Thessaloniki
133	University General Hospital	Psyrri, Amanda	Greece	NA	Athens
134	General Hospital of Athens of Chest Diseases	Syrigos, Konstantinos	Greece	NA	Athens
135	A.O.U. Policlinico di Modena	Bertolini, Federica	Italy	Modena	Modena
136	Azienda Ospedaliera Universitaria Careggi	Livi, Lorenzo	Italy	Firenze	Firenze
137	IEO Istituto Europeo di Oncologia	Nole, Franco	Italy	Milano	Milano
138	Fondazione del Piemonte per l'Oncologia IRCC Candiolo Piedmont Foundation for Oncology IRCC Candiolo	Galizia, Danilo	Italy	Torino	Candiolo
139	Ospedale San Raffaele	Mirabile, Aurora	Italy	Milano	Milano
140	IOV - Istituto Oncologico Veneto IRCCS	Ghi, Mariagrazia	Italy	Padova	Padova
141	Fondazione Policlinico Universitario Agostino Gemelli IRCCS Agostino Gemelli University Hospital Foundation IRCCS	Valentini, Vincenzo	Italy	Roma	Roma
142	Fondazione IRCCS Istituto Nazionale dei Tumori	Licitra, Lisa	Italy	Milano	Milano
143	Ospedale Oncologico Armando Businco	Ghiani, Massimo	Italy	Cagliari	Cagliari
144	IRCCS Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori IRCCS Romagna Scientific Institute for the Study and Treatment of Tumors	De Rosa, Francesco	Italy	Forli - Cesena	Meldola
145	Azienda Ospedaliera Universitaria Policlinico Umberto I - Universita di Roma La Sapienza Azienda Ospedaliera Universitaria Policlinico Umberto I - University of Rome La Sapienza	Botticelli, Andrea	Italy	Roma	Roma
146	Azienda Ospedaliera Universitaria- Universita degli Studi della Campania “Luigi Vanvitelli” University Hospital - University of Campania "Luigi Vanvitelli"	Fasano, Morena	Italy	Napoli	Napoli
147	Istituto Nazionale Tumori Fondazione G. Pascale	Perri, Francesco	Italy	Napoli	Napoli
148	Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)	Buglione, Michela	Italy	Brescia	Brescia
149	UMC Utrecht	De Ridder, Mischa	Netherlands	NA	Utrecht
150	Universitair Medisch Centrum Groningen	Oosting, Sjoukje	Netherlands	NA	Groningen
151	Amsterdam UMC, Locatie VUMC	Buter, Jan	Netherlands	NA	Amsterdam
152	Centrum Onkologii-Instytut im.M.Sklodowskiej Curie Oncology Centre-Institute of M. Skłodowska-Curie	Rutkowski, Tomasz	Poland	NA	Gliwice
153	Hospital de Braga	Ferreira Pereira, Filipa Margarida	Portugal	NA	Braga
154	Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE	Vieira, Claudia	Portugal	NA	Porto
155	Centro Hospitalar de Sao Joao, E.P.E	Coelho, Andreia	Portugal	NA	Porto
156	Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E.	Monteiro, Ana	Portugal	NA	Vila Nova de Gaia
157	S.C Medisprof S.R.L	Udrea, Anghel Adrian	Romania	NA	Cluj-Napoca
158	S.C Radiotherapy Center Cluj S.R.L	Ungureanu, Andrei	Romania	NA	Comuna Floresti
159	S.C Oncocenter Oncologie Clinica S.R.L	Scheusan, Roxana-Ioana	Romania	NA	Timisoara
160	S.C Centrul de Oncologie Sf. Nectarie S.R.L	Schenker, Michael	Romania	NA	Craiova
161	Centrul medical Focus	Iordan, Ingrid	Romania	NA	Bucuresti
162	Hospital Universitario Virgen del Rocio	Flor Oncala, Maria Jose	Spain	Sevilla	Sevilla
163	Clinica Universidad de Navarra (MAD)	Serrano, Javier	Spain	Madrid	Madrid
164	Hospital Regional Universitario de Malaga	Rueda Dominguez, Antonio	Spain	Malaga	Malaga
165	Hospital Universitario Fundacion Jimenez Diaz	Rubio Perez, Jaime	Spain	Madrid	Madrid
166	Hospital Universitario Lucus Augusti	Hospital Universitario Lucus Augusti	Spain	Lugo	Lugo
167	Complejo Hospitalario Universitario Insular Materno-Infantil	Gomez de Liano Lista, Alfonso	Spain	Las Palmas	Las Palmas de Gran Canaria
168	Hospital del Mar	Corbera, Alex	Spain	Barcelona	Barcelona
169	ICO l'Hospitalet - Hospital Duran i Reynals	Oliva Bernal, Marc	Spain	Barcelona	L'Hospitalet de Llobregat
170	Hospital Universitari Vall d'Hebron	Giralt Lopez de Sagredo, Jordi	Spain	Barcelona	Barcelona
171	ICO Badalona - Hospital Universitari Germans Trias i Pujol	Ferrando, Angelica	Spain	Barcelona	Barcelona
172	Complejo Hospitalario Universitario A Coruna	Molina, Aurea	Spain	La Coruna	A Coruna
173	Hospital Universitario La Paz	Castelo Fernandez, Beatriz	Spain	Madrid	Madrid
174	Hospital Clinic de Barcelona	Baste Rotllan, Neus	Spain	Barcelona	Barcelona
175	Universitaetsspital Basel	Bunea, Andrei	Switzerland	NA	Basel
176	CHUV, Lausanne University Hospital	Cristina, Valérie	Switzerland	NA	Lausanne
177	Universitaetsspital Zuerich	Balermpas, Panagiotis	Switzerland	NA	Zuerich
178	Istituto Oncologico della Svizzera Italiana (IOSI)- Ente Ospedaliero Cantonale (EOC) Institute of Oncology of Southern Switzerland (IOSI) - Ente Ospedaliero Cantonale (EOC)	Espeli, Vittoria	Switzerland	NA	Bellinzona
179	Inonu Uni. Med. Fac.	Harputluoglu, Hakan	Turkey	NA	Malatya
180	Gazi University Medical Faculty	Yazici, Ozan	Turkey	NA	Ankara
181	Trakya University Medical Faculty	Hacioglu, Bekir	Turkey	NA	Edirne
182	Adana City Hospital	Cil, Timucin	Turkey	NA	Adana
183	Izmir Medicalpark Hospital	Arslan, Cagatay	Turkey	NA	Izmir
184	Medipol University Medical Faculty	Bilici, Ahmet	Turkey	NA	Istanbul
185	Mount Vernon Hospital	Chiu, Kevin	United Kingdom	Middlesex	Middlesex
186	Royal Surrey County Hospital	Mehta, Ajay	United Kingdom	Surrey	Guildford
187	Clatterbridge Cancer Centre	Clatterbridge Cancer Centre	United Kingdom	Merseyside	Wirral
188	St James's University Hospital	Sen, Mehmet	United Kingdom	West Yorkshire	Leeds
189	Western General Hospital	Western General Hospital	United Kingdom	Lothian Region	Edinburgh
190	The Christie Hospital	Hughes, Christopher	United Kingdom	Greater Manchester	Greater Manchester
191	中南大学湘雅医院 Xiangya Hospital, Central South University	申良方 Shen Liangfang	中国 China	湖南省 Hunan Province	长沙市 Changsha city
192	北京肿瘤医院 Beijing Cancer Hospital	孙艳 Sun Yan	中国 China	北京市 Beijing	北京市 Beijing
193	上海市第一人民医院 Shanghai First People's Hospital	董频 Dong Pin	中国 China	上海市 Shanghai	上海市 Shanghai
194	河南省肿瘤医院 Henan Provincial Cancer Hospital	吴慧 Wu Hui	中国 China	河南省 Henan Province	郑州市 Zhengzhou City
195	安徽省肿瘤医院 Anhui Provincial Cancer Hospital	高劲 Gao Jin	中国 China	安徽省 Anhui Province	合肥市 Hefei City
196	中山大学肿瘤防治中心 (中山大学附属肿瘤医院) Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital)	吴少雄 Wu Shaoxiong	中国 China	广东省 Guangdong Province	广州市 Guangzhou City
197	南京鼓楼医院 Nanjing Drum Tower Hospital	闫婧 Yan Jing	中国 China	江苏省 Jiangsu Province	南京市 Nanjing
198	中国医科大学附属盛京医院 Shengjing Hospital Affiliated to China Medical University	刘彩刚 Liu Caigang	中国 China	辽宁省 Liaoning Province	沈阳市 Shenyang city
199	蚌埠医学院第一附属医院 The First Affiliated Hospital of Bengbu Medical College	张亚军 Zhang Yajun	中国 China	安徽省 Anhui Province	蚌埠市 Bengbu City
200	西安交大附属二院 The Second Affiliated Hospital of Xi'an Jiaotong University	马红兵 Ma Hongbing	中国 China	陕西省 Shaanxi Province	西安市 Xi'an City
201	Institut Jules Bordet	Awada, Ahmad	Belgium	NA	Anderlecht
202	High Technology Hospital Medcenter LLC	Makharadze, Tamta	Georgia	NA	Batumi
203	Evex Hospitals Oncology Center	Natelauri, Eter	Georgia	NA	Kutaisi
204	Cancer Research Center Ltd.	Matitashvili, Amiran	Georgia	NA	Tbilisi
205	Musgrove Park Hospital	Jankowska, Petra	United Kingdom	Somerset	Taunton
206	Royal Marsden Hospital- London	Harrington, Kevin	United Kingdom	Greater London	London

序号 serial number	名称 name	审查结论 Conclusions of the review	批准日期/备案日期 Approval Date/Filing Date
1	华中科技大学同济医学院附属协和医院医学伦理委员会 Medical Ethics Committee of Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology	同意  agree	2022-08-02
2	华中科技大学同济医学院附属协和医院医学伦理委员会 Medical Ethics Committee of Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology	同意  agree	2023-02-27
3	华中科技大学同济医学院附属协和医院医学伦理委员会 Medical Ethics Committee of Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology	同意  agree	2023-12-06

进行中 （招募中）   Ongoing (Recruiting)

目标入组人数 Target enrollment	国内: 83 ； 国际: 700 ；  Domestic: 83 ; International: 700 ;
已入组人数 Number of people enrolled	国内: 19 ； 国际: 89 ；  Domestic: 19 ; International: 89 ;
实际入组总人数 The total number of people actually enrolled	国内: 登记人暂未填写该信息； 国际: 登记人暂未填写该信息； Domestic: The registrant has not filled in this information yet; International: The registrant has not filled in this information yet;

第一例受试者签署知情同意书日期 The date on which the first subject signed the informed consent form	国内：2022-10-06；     国际：2023-01-16； Domestic:2022-10-06;     International:2023-01-16;
第一例受试者入组日期 Date of enrollment of the first subject	国内：2022-10-21；     国际：2023-02-12； Domestic:2022-10-21;     International: 2023-02-12;
试验完成日期  The date of completion of the experiment	国内：登记人暂未填写该信息；     国际：登记人暂未填写该信息； Domestic: The registrant has not filled in this information yet;     International: The registrant has not yet filled in this information;

序号 serial number	版本号 Version number	版本日期 Version date
暂未填写此信息 This information is not filled in yet